FDA approves Sanofi's Infilbray as first US treatment for neurological Type 3 Gaucher disease

Sanofi said Nov. 18 that the U.S. Food and Drug Administration approved Infilbray (venglustat), a once-daily oral pill, to treat the neurological manifestations of Type 3 Gaucher disease in adults and in children weighing at least 15 kilograms. The Paris-based drugmaker described Infilbray as the first medicine cleared in the United States for the brain-related symptoms of the rare inherited disorder, a part of the disease that existing infused therapies do not reach. The decision arrived a week ahead of the Nov. 25 target action date the agency had set when it granted the application priority review in May.
Key developments
- The FDA approved Infilbray, an oral glucosylceramide synthase inhibitor designed to cross the blood-brain barrier, for neurological manifestations of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg.
- Approval rests on the Phase 3 LEAP2MONO trial, in which 43 patients aged 12 and older were randomized 1:1 to Infilbray or intravenous imiglucerase every two weeks. Infilbray showed statistically significant superiority on a combined motor and cognitive endpoint at week 52 (p=0.0137).
- The label carries warnings for suicidal ideation and behavior, lens opacification in pediatric patients and embryofetal toxicity.
- The drug held Breakthrough Therapy, Rare Pediatric Disease and Fast Track designations in the U.S. and orphan status in the U.S., EU and Japan. It remains under review in the EU, Japan and other jurisdictions.
Disease background
Gaucher disease is a lysosomal storage disorder caused by a deficiency of the enzyme glucocerebrosidase. Without enough working enzyme, fatty glycosphingolipids build up mainly in the spleen, liver, bone marrow and lungs. Physicians recognize three forms. Type 1 has no primary central nervous system involvement, Type 2 is an acute neuronopathic form, and Type 3 is a chronic neuronopathic form in which lipid accumulation in the brain drives neuroinflammation, cognitive deficits and ataxia alongside an enlarged liver and spleen, anemia, low platelet counts and bone disease.
For decades, care has centered on enzyme replacement therapy delivered by infusion every two weeks, plus oral substrate reduction drugs for Type 1. Those therapies can control the blood, organ and bone effects of the disease. Enzyme replacement does not cross the blood-brain barrier, however, and the oral substrate reduction drug eliglustat is excluded from the brain. Pharmacy Times reported that miglustat, another oral option, proved ineffective for neurological symptoms. Dr. Pramod Mistry, director of the Yale Lysosomal Disease Center, said in Sanofi's release that the neurological manifestations had remained out of reach even as systemic symptoms became treatable.
Venglustat works upstream. By inhibiting glucosylceramide synthase, it aims to cut production of the lipids that accumulate, and its ability to enter the brain is what distinguishes it from the earlier oral agent in its class.
Industry implications
The approval converts a long-running neurology program into Sanofi's first commercial product aimed at the central nervous system effects of a lysosomal storage disease. The LEAP2MONO design matters here. Rather than testing venglustat against placebo, Sanofi compared it head to head with imiglucerase, the standard infused therapy, in patients who had already met their systemic treatment goals after at least three years on enzyme replacement. The trial therefore asked whether a single oral drug could hold systemic control while adding neurological benefit.
The answer, on the primary analysis, was yes on the combined motor and cognitive measure. Sanofi's May filing release said the study also met three of four key secondary endpoints, which Pharmacy Times identified as spleen volume, liver volume and hemoglobin. Safety will shape uptake. Diarrhea, splenomegaly and nausea each occurred in 14% of Infilbray patients in the primary period, and depression and gastroenteritis each in 10%, against low rates in the imiglucerase arm. With 21 patients on drug, each percentage reflects only a few people, and prescribers will look to the ongoing open-label extension for durability and longer-term safety.
The label's psychiatric and pediatric eye warnings also point to monitoring requirements, which specialist treatment centers are already set up to manage for a disease of this rarity.
Competitive and supply chain implications
Sanofi already sells imiglucerase as Cerezyme and eliglustat as Cerdelga, so Infilbray extends a franchise rather than displacing a rival's product. Its practical effect is to give GD3 patients an oral alternative to biweekly infusions while targeting symptoms no competitor addresses. Other enzyme replacement therapies on the market, including Takeda's velaglucerase alfa and Pfizer's taliglucerase alfa, act outside the brain, which leaves Sanofi with a clear first-mover position in neuronopathic disease.
From a supply perspective, a daily small-molecule tablet is simpler to manufacture, ship and dispense than a biologic that requires cold-chain handling and infusion chairs. That shift could move some care from infusion centers to the home, with implications for specialty pharmacies and the home-infusion providers that serve Gaucher patients today. Sanofi did not disclose launch timing or pricing in its release.
Regional implications
The U.S. decision is the first for the drug. Sanofi said venglustat is under review for GD3 in the European Union, Japan and other jurisdictions, and it plans further global submissions in 2026 and 2027. Because GD3 patients are spread thinly across many countries, the pace of approvals and reimbursement outside the U.S. will largely determine how many patients gain access, and orphan designations already in place in the EU and Japan carry incentives for those reviews.
In Europe, the outcome of the review will also test how health technology assessment bodies value a neurological benefit measured on composite motor and cognitive scales in a 43-patient trial, a common challenge for ultra-rare disease medicines.
Credence Research analysis
The approval stands out less for its patient numbers than for what it proves about brain-penetrant substrate reduction. Lysosomal storage disorders with central nervous system involvement have long been the hardest part of the field, because the biologics that transformed systemic disease cannot cross into the brain. A positive, active-controlled Phase 3 result with an oral small molecule gives developers in this space a regulatory precedent: the FDA accepted a global test combining motor and cognitive scores as the basis for approval. That precedent may be as valuable to the wider rare neurology pipeline as the product itself.
For Sanofi, Infilbray reinforces a rare-disease business built on Cerezyme and Cerdelga, and it lets the company keep GD3 patients within its portfolio as they move from infusion to oral therapy. The key uncertainties are durability and tolerability. The psychiatric warning and the gastrointestinal events seen in a small trial will need longer follow-up, and the open-label data Sanofi has promised will be the next real test of whether early neurological gains hold.
What comes next
- Sanofi to set U.S. launch timing and pricing, which were not disclosed with the approval.
- Regulatory decisions on venglustat for GD3 in the EU and Japan, where reviews are ongoing.
- Additional global regulatory submissions planned across 2026 and 2027.
- Presentation of open-label extension results from LEAP2MONO on durability and long-term safety.
- Payer and health technology assessment reviews of the composite neurological endpoint in Europe and other markets.
Sources
- Sanofi: Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease (Nov. 18, 2026)
- Sanofi: Venglustat accepted for priority review in the US to treat Type 3 Gaucher disease (May 28, 2026)
- Pharmacy Times: FDA approves venglustat, first treatment for neurological symptoms of GD3
Image: Sanofi pharmaceutical plant in Chattanooga, Tennessee, by Harrison Keely via Wikimedia Commons, CC BY 4.0. Cropped and edited by Credence Research.
About the Author

Senior News Editor at Credence Research Inc